Kakinada, Andhra Pradesh – In a significant step for India’s pharmaceutical industry, Prime Minister Narendra Modi virtually inaugurated Lyfius Pharma’s flagship Penicillin-G (Pen-G) manufacturing facility in Kakinada on October 29, 2024.
This new facility, with an investment of ₹2,500 crores under the Production Linked Incentive (PLI) scheme, aims to reduce India’s dependency on imports by enhancing the production of essential pharmaceutical components. The plant, which has an annual production capacity of 15,000 metric tonnes, is set to start commercial production in the fiscal year 2025.
Also read | Cabinet Approves Two Railway Projects Worth Rs 6,798 Crore in Andhra Pradesh and Bihar
Key Figures Present at the Event
The inauguration saw the virtual presence of Union Minister Shri Jagat Prakash Nadda, Dr. Mansukh Mandaviya, and other key government officials. Speaking on the occasion, Lyfius Pharma’s Director, Mr. M.V. Rama Krishna, highlighted the company’s commitment to support “Atmanirbhar Bharat” by bolstering domestic production of critical drug intermediates and active pharmaceutical ingredients.
Enhancing Healthcare Self-Sufficiency
The facility is one of the largest fermentation-based antibiotic intermediate plants in India. Equipped with advanced technology, it reinforces India’s capabilities to meet both domestic and international demand for Penicillin-G.
